HealthQuill US
Bristol Myers Squibb’s end-phase trial to test a drug for treating a heart condition, where the muscle of the heart's main pumping chamber becomes abnormally thickened, has failed to meet its goals.
Drugs Health Medical

Bristol Myers’ test drug to treat a type of heart disease fails to meet goals

HQ Team April 15, 2025: Bristol Myers Squibb’s end-phase trial to test a drug for treating a heart condition, where the muscle of.

Read More
AstraZeneca’s combination drug for the treatment of adults with resectable non-small cell lung cancer has got approval from the European Union.
Drugs Health Pharma

AstraZeneca’s lung cancer drug combination gets EU approval 

HQ Team April 4, 2025: AstraZeneca’s combination drug for the treatment of adults with resectable non-small cell lung cancer has got approval from.

Read More
Amgen Inc.’s treatment for adults living with immune-mediated inflammatory conditions was granted regulatory approval by the US Food and Drug Administration, according to a statement.
Drugs Health Medical

Amgen gets US approval to treat immunoglobulin G4-related disease 

HQ Team April 4, 2025: Amgen Inc.’s treatment for adults living with immune-mediated inflammatory conditions was granted regulatory approval by the US Food and.

Read More
The US Food and Drug Administration has rejected the biotechnology company Aldeyra Therapeutics Inc’s investigational drug for treating dry eyes, over concerns with the data from the trial.
Drugs Health Medical

Aldeyra Therapeutics’ dry eye treatment rejected by USFDA

HQ Team April 3, 2025: The US Food and Drug Administration has rejected the biotechnology company Aldeyra Therapeutics Inc’s investigational drug for treating.

Read More
Organon has acquired the commercial rights for a biosimilar for intravenous infusion in treating arthritis and Covid-19 from Biogen Inc., for an undisclosed amount.
Drugs Medical Pharma

Organon & Co. buys biosimilar from Biogen for an undisclosed sum

HQ Team April 2, 2025: Organon has acquired the commercial rights for a biosimilar for intravenous infusion in treating arthritis and Covid-19 from.

Read More
Merck & Co., Inc. has bought global rights for an experimental oral drug to treat heart diseases from China’s Jiangsu Hengrui Pharmaceuticals Co., Ltd. in a $2 billion deal.
Drugs Health Pharma

Merck signs $2b licensing deal with Jiangsu Hengrui for heart disease drug

HQ Team March 25, 2025: Merck & Co., Inc. has bought global rights for an experimental oral drug to treat heart diseases from.

Read More
US scientists have blocked a protein that kills a variety of cancer cells in an experiment on mice, pointing to a new potential target for cancer treatment, according to the National Institutes of Health.
Drugs Health Research

US scientists block proteins that aid cancer cells’ group strategy to survive

HQ Team March 5, 2025: US scientists have blocked a protein that kills a variety of cancer cells in an experiment on mice,.

Read More
Tau proteins in brain neurons can form neurofibrillary tangles, which are a hallmark of Alzheimer's disease, and these abnormal proteins also accumulate in the dying cells in the retina of the eyes of the patients with the condition, investigators at Cedars-Sinai Medical Center found.
Health Pharma Research

Abnormal protein accumulation in patient’s eyes linked to Alzheimer’s

HQ Team March 4, 2025: Tau proteins in brain neurons can form neurofibrillary tangles, which are a hallmark of Alzheimer’s disease, and these.

Read More
AbbVie Inc. will license a drug to treat obesity from Denmark’s Gurba A/S, a preclinical contract research services and peptide-based drug discovery, for about $2.2 billion to mark its entry into the obesity treatment space.
Drugs Medical Pharma

AbbVie inks $2.2b deal with Denmark’s Gurba, enters weight-loss market

 HQ Team March 4, 2025: AbbVie Inc. will license a drug to treat obesity from Denmark’s Gurba A/S, a preclinical contract research services.

Read More
Eli Lilly will set up four new pharmaceutical manufacturing facilities in the US for $27 billion to further bolster its supply chains, according to a statement.
Drugs Medical Pharma

Eli Lilly to set up four manufacturing facilities in US for $27 billion

Eli Lilly will set up four new pharmaceutical manufacturing facilities in the US for $27 billion to further bolster its supply chains, according.

Read More